Table A.1:
Select pharmacogenetic variants and carrier status genes with analyzed by CES at conclusion of the triala
| Association | |
|---|---|
| Pharmacogenetic Variants | |
| CYP2C19*2, *3 | Impaired responsiveness to Clopidogrel |
| CYP2C9*2, *3,*4,*5,*6,*9,*11 | Warfarin sensitivity |
| CYP4F2*3 | Warfarin resistance |
| DPYD*2A, c.496A>G/M166V | Dihydropyrimidine dehydrogenase deficiency |
| SCL01B1*5 | Statin induced myopathy |
| TPMT*2,*3A,*3B,*3C,*4 | 6-mercaptopurine sensitivity; Azathioprine sensitivity |
| Carrier Status Genes | |
| ACADM | Medium Chain Acyl-CoA Dehydrogenase Deficiency |
| BCHE | Pseudocholinesterase Deficiency |
| CFTR | Cystic fibrosis |
| G6PC | Glycogen Storage Disease, Type 1A |
| GBA | Gaucher disease |
| GJB2 | GJB2-related DFNB1 hearing loss |
| HBB | Beta thalassemia |
| HEXA | Tay-Sachs |
| PAH | Phenylalanine Hydroxylase Deficiency(PKU) |
| SERPINA1 | Alpha-1 Antitrypsin deficiency |
a.
The pharmacogenetic variants list was dynamic throughout the course of the study and not all participants randomized to CES had carrier status genes annotated.